Legal News

A recent report showing slowing US manufacturing activity and a sliding 10-year Treasury note yield is only making Chair Powell’s balancing act that much tougher....By: Robins Kaplan LLP

A survey of the country’s most powerful CEOs by the Business Roundtable shows an interesting shift in how they view their top priority—no longer does advancing the interests of shareholders take the top spot. Instead, the leaders identified investing...By: Robins Kaplan LLP

Wall Street’s post-tariff-delay jubilance was short lived, as an inverted bond yield curve reared its ugly head yesterday, sending shares plummeting on a brutal day across all markets....By: Robins Kaplan LLP

In the internal battle between keeping China off balance and keeping Wall Street happy, the White House has decided once again to focus on the latter, walking back the latest tariff escalation by postponing promised enforcement until mid-December, a...By: Robins Kaplan LLP

A volatile August on Wall Street has insiders asking whether we should be taking our cues from 1998 or 2007. With that in mind, our financial term of the week is “countercyclical capital buffer,” a wonkish special for you econ diehards out there...By: Robins Kaplan LLP

Saudi Aramco’s mega IPO plans are back on, and while valuation and other stumbling blocks remain, the kingdom is hoping to raise billions via the public offering as early as next year....By: Robins Kaplan LLP

Last week’s wild economic ride combined with China’s currency-devaluing response (and, arguably, months more of trade-war-driven global uncertainty) led to the worst day on Wall Street since last December, with the Dow plummeting more than 700 points...By: Robins Kaplan LLP

HSBC chief John Flint is out just 18 months after he assumed the role as head of the London-based bank, likely due to clashes with Board Chair Mark Tucker and the lender’s focus on expanding in China. HSBC also announced it will shed 4,000 jobs in an...By: Robins Kaplan LLP

Apparently hoping to urge China off of its new go-slow tactic, the White House is applying its maximum pressure campaign again, announcing yesterday that the US will “impose a 10 percent tariff on an additional $300 billion worth of Chinese imports...By: Robins Kaplan LLP

Drug giants Pfizer and Mylan have inked a deal that will merge the former’s off-patent drugs with the latter’s generics business, a tie-up that creates a mammoth global seller of lower-priced medicines....By: Robins Kaplan LLP